The HIV Research for Prevention conference (HIVR4P) was held in Madrid, Spain, from 21 to 25 October 2018.

Conference highlights

New and experimental HIV treatments

First large HIV prevention trial using antibodies will probably not be the last.

Conference bulletin

Read our HIVR4P news summary bulletin.

PrEP science

Beyond Truvada – what is the future of PrEP?

The search for a cure

The Miami monkey cured with two antibodies.

PrEP science

Boston HIV clinic sees 90% reduction in infections in people being prescribed PrEP.

PrEP science

The long tail of injectable PrEP is especially long for women.

PrEP programmes & uptake

380,000 people on PrEP globally, mostly in the USA and Africa.


Going local – prevention conference hears about rings, douches, and soluble suppositories

PrEP programmes & uptake

Far more people may be using PrEP than we know, HIV prevention conference hears.

aidsmap news from HIVR4P 2018

← First1Next →

Editors' picks from other sources

News bulletins

Sign up for our email bulletins

Find out more and sign up to the full range of aidsmap email bulletins >

Official conference website

Find out more on the official conference website.

Visit the conference website >

Conference bulletin

Visit our HIVR4P 2018 conference bulletin page.

HIVR4P 2018 conference bulletin >
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.